- Home
- ELMD vs EDIT Comparison
ELMD vs EDIT Comparison
Compare ELMD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELMD | EDIT |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 206.0M |
| IPO Year | 2010 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ELMD | EDIT |
|---|---|---|
| Price | $23.07 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $36.00 | $4.92 |
| AVG Volume (30 Days) | 42.6K | ★ 1.6M |
| Earning Date | 02-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | 37.50 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $54,716,000.00 | $31,937,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $41.86 | ★ N/A |
| Revenue Growth | 13.83 | ★ 132.64 |
| 52 Week Low | $17.73 | $0.91 |
| 52 Week High | $30.73 | $4.54 |
Technical Indicators
Market Signals| Indicator | ELMD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 53.26 |
| Support Level | $17.87 | $1.84 |
| Resistance Level | $25.38 | $2.36 |
| Average True Range (ATR) | 0.76 | 0.18 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 16.67 | 52.91 |
Price Performance
Historical ComparisonAbout ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.